Related Experiment Video
Updated: Apr 29, 2026
How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
Published on: December 14, 2014
Placebo in Paediatric Clinical Trials: Systematic Literature Review and Framework-Based Synthesis
Georgia Parry1, Artur Abelian1, Chloe C E Williams2,3
1Department of Paediatrics, Maelor Hospital, Wrexham, UK.
Insights
Placebo use in pediatric clinical trials is ethically acceptable only under strict conditions, prioritizing scientific necessity, minimizing harm, and ensuring robust safeguards and consent processes for children.
Area of Science:
- Pediatric Clinical Research Ethics
- Regulatory Science
- Evidence-Based Medicine
Background:
- Placebo-controlled trials offer strong evidence but raise ethical concerns in pediatric research due to limited decisional capacity and potential withholding of effective treatments.
- The ethical acceptability of using placebos in trials involving children is a significant and debated issue in medical research.
Purpose of the Study:
- To systematically review and identify the specific ethical and methodological conditions that permit the use of placebo controls in pediatric clinical trials.
- To synthesize findings from literature and regulatory guidance to establish criteria for ethical placebo use in pediatric research.
Main Methods:
- A systematic review of literature from Medline, Scopus, and Embase was conducted, focusing on ethics, acceptability, and regulation of placebo use in pediatric trials.
- Extracted study characteristics and ethical arguments were mapped to core ethical principles (beneficence, non-maleficence, autonomy, justice).
- Findings were synthesized using established ethical research frameworks, supplemented by expert guidance from international regulators (UK, USA, Europe).
Main Results:
- 51 sources were included, covering neonatal, disease-specific, and general ethical/regulatory aspects of pediatric placebo trials.
- Placebos were deemed acceptable when methodologically essential, scientifically valid, and when withholding treatment posed minimal risk.
- Crucial safeguards included rescue therapy, early escape options, close monitoring, limited non-beneficial risk, and robust assent/permission procedures.
Conclusions:
- The use of placebos in pediatric trials is permissible only under specific, constrained conditions.
- These conditions emphasize scientific necessity, minimizing harm from withheld therapies, implementing strong safeguards, and ensuring appropriate consent and assent.
- Further development of disease-specific operational guidance is recommended to translate these ethical conditions into practice.
Introduction:
Placebo-controlled trials can provide strong evidence on safety and efficacy, but their ethical acceptability in paediatric research is contested because children have limited decisional capacity and placebo use may entail withholding effective therapy.
Objective:
To identify the ethical and methodological conditions under which placebo controls are acceptable in paediatric clinical trials, using a systematic review of the literature and regulatory guidance.
Methods:
We searched Medline, Scopus and Embase for sources addressing the ethics, acceptability or regulation of placebo use in paediatric trials. We extracted study characteristics and ethical arguments, mapped them to beneficence, non-maleficence, autonomy and justice, and then synthesised findings using Emanuel, Wendler and Grady's seven requirements for ethical clinical research. We also obtained expert guidance from UK, USA and European regulators.
Results:
We included 51 sources spanning neonatal research, disease-specific paediatric contexts, parental perspectives and general ethics/regulatory discussions. Placebo was generally considered acceptable when methodologically necessary and scientifically sound, when no proven effective therapy was withheld (or any withholding carried minimal incremental risk), and when safeguards such as rescue therapy, early escape, and close monitoring were in place. Common emphases included limits on non-beneficial risk in children, assent and parental permission, and fair participant selection.
Conclusion:
Placebo use in paediatric trials is acceptable only under constrained conditions centred on scientific necessity, minimising harm from withholding therapy, robust safeguards and appropriate permission/assent processes. Further work should translate these conditions into disease-specific, operational guidance.
Related Concept Videos
01:54The Placebo Effect
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:11Blinding
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion